AttardLab

248 posts

AttardLab banner
AttardLab

AttardLab

@AttardLab

Understanding treatment resistance in prostate cancer @uclcancer. Tweets by Gert & team.

Katılım Ocak 2018
244 Takip Edilen1.2K Takipçiler
AttardLab retweetledi
Alison Tree 💙
Alison Tree 💙@alison_tree·
About time! Good news for those men currently paying out of pocket for Abiraterone and great news for all men who will benefit in future. Well done @ProstateUK for your relentless campaigning to right this wrong.
Prostate Cancer UK@ProstateUK

BREAKING NEWS 📢 Abiraterone has been approved for use on the NHS for men in England with #ProstateCancer that has a high risk of spreading. Over the next five years, this decision will save the lives of 3,000 men. ➡️ Read more: bit.ly/3NxcMYa

English
1
6
26
4.2K
AttardLab retweetledi
Advanced Prostate Cancer Consensus Conference
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·
🚨 Big News from #APCCC26 🚨 APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! Full details & submission 👉 apccc.org 📅 Key Dates: 🔹 Submission opens: 1 Sept 2025 🔹 Deadline: 14 Nov 2025, 23:59 CET 🔹 Notifications: 19 Dec 2025 ✅ Complimentary registration for presenting authors. ✅ Travel grants available for LMIC investigators. ✅ Selected abstracts will be presented as posters in Lugano (30 Apr–1 May 2026). Categories: Advanced prostate cancer Side effects & QoL/PROs Global access to therapies @Silke_Gillessen & @AOmlin @OncoAlert 🚨 @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun @DrChoueiri @tompowles1 @brian_rini Ping @nataliagandur @bavilima @yekeduz_emre
English
0
16
18
6.6K
AttardLab retweetledi
silke gillessen
silke gillessen@Silke_Gillessen·
The mHSPC space becomes more and more interesting! Come and participate in the discussions @APCCC_Lugano register via apccc.org!
silke gillessen tweet media
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study out on Annals of Oncology annalsofoncology.org/article/S0923-… CAPItello-281 In PTEN-deficient metastatic hormone-sensitive #ProstateCancer , adding the AKT inhibitor capivasertib to abiraterone and ADT significantly prolonged radiographic progression-free survival with manageable, expected toxicities. Karim Fizazi @mdesantis234 @M_SoteloLezama @Daniel_J_George @OncoAlert 🚨 @silkegillessen @AOmlin @nataliagandur @bavilima

English
1
10
37
5.1K
AttardLab retweetledi
Michael Hofman
Michael Hofman@DrMHofman·
@AzadOncology asking the question- do all patients need six cycles of Lu-PSMA in #PSMAaddition? Showing a nice example of complete response after two cycles on #UpFrontPSMA
Berlin, Germany 🇩🇪 English
0
13
28
1.8K
AttardLab retweetledi
Oscar Tahuahua
Oscar Tahuahua@OscarTahuahua·
CAPItello-281 In de novo PTEN-deficient mHSPC (poor prognosis), capivasertib + abiraterone ↑ rPFS vs pbo + abiraterone (33.2 vs 25.7 mo; HR 0.81; P=0.034), OS immature. ↑ PTEN loss correlated with ↑ benefit; POTENTIAL for now With Amplitude trial paving the way, NGS is key in mHSPC How should we integrate this combo when triplet is already available? @OncoAlert @myESMO #ESMO25
Oscar Tahuahua tweet mediaOscar Tahuahua tweet mediaOscar Tahuahua tweet mediaOscar Tahuahua tweet media
Oscar Tahuahua@OscarTahuahua

#ESMO25 Ph III CAPItello 281: Capivasertib + Abiraterone vs pbo + Abi in PTEN-deficient de novo mHSPC rPFS 33.2 vs 25.7 mo (HR 0.81); OS not yet mature ⚠️ A promising first in class targeted option for this poor-prognosis population Benefit ↑ w/greater PTEN loss, emphasizing the need for biomarker based 1L treatment as seen with BRCA/HRR @OncoAlert

English
0
10
29
2.9K
AttardLab
AttardLab@AttardLab·
@GIZZIMarcoMd Decipher high is the sole BM we pre-defined and had a stat sig p value for an interaction with doce effect. Ie prediction. But I agree that prognostic tests are imp - if patient will not progress, no benefit from doce
English
0
0
0
35
GIZZI Marco
GIZZI Marco@GIZZIMarcoMd·
@AttardLab Triplet upfront for all mHSPC—or only the truly aggressive ones? De novo, high‑volume, PSA > 0.2 @ 12 wk, PTEN‑loss profile may define who really needs escalation. For others, are we overtreating?
English
1
0
0
83
AttardLab
AttardLab@AttardLab·
STAMPEDE update at #ESMO25today at noon. Landmark analysis of 7,129 pts shows PSA ≤0.2 ng/mL by 6–12 weeks strongly predicts OS in HSPC. Prognostic value modified by metastatic volume & nodal status. Abiraterone ± enzalutamide delivers deepest PSA responses & best survival.
English
3
6
23
1.7K
AttardLab retweetledi
Rana McKay, MD, FASCO
Rana McKay, MD, FASCO@DrRanaMcKay·
Wonderful discussion by ⁦@Prof_Nick_James⁩ on EnzaRad highlighting the differences between Stampede. Lower risk group enrolled and differential effect of ARPI in higher risk group. #ESMO25 ⁦@myESMO⁩ ⁦@OncoAlert⁩
Rana McKay, MD, FASCO tweet mediaRana McKay, MD, FASCO tweet mediaRana McKay, MD, FASCO tweet media
English
2
12
25
1.7K
AttardLab
AttardLab@AttardLab·
EnzaRad P3 trial confirms boundary of patient benefit sits somewhere between STAMPEDE ultra HR and NCCN HR. Working together we will use BM to define this #ESMO25
English
0
2
11
964
AttardLab retweetledi
Tom Powles
Tom Powles@tompowles1·
ALBAN #ESMO25 (atezolizumab/BCG vs BCG in MIBC) @Annals_Oncology did not ⬆️ EFS (HR0.97) unlike sasalimab & durvalumab in a similar setting. The drugs seem similar in metastatic UC so was it trial design making it different from other ICIs? EFS was defined differently.
Tom Powles tweet mediaTom Powles tweet mediaTom Powles tweet media
English
4
27
62
6.5K
AttardLab
AttardLab@AttardLab·
🧪Sequential liquid biopsies reveal ctDNA features and dynamics linked to survival & resistance in advanced #ProstateCancer patients treated with cabazitaxel.
🧬 cell cycle gene amplification associates with taxane resistance 🤝Results from an international collaborative effort
English
0
0
0
219
AttardLab
AttardLab@AttardLab·
#EMUC promising to be a great meeting
AttardLab tweet media
English
0
0
3
325
AttardLab
AttardLab@AttardLab·
Exciting
AttardLab tweet media
English
0
0
4
309

Keşfet

@EmilyGrist1 @ChrisSweens1 @ProstateUK @Ecastromarcos @Silke_Gillessen @AOmlin @OncoAlert @fabioturco92